SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andreu Nubiola, Marga Ferrer, Imma Remolins, La asociación de hiperinsulinemia con riesgo cardiovascular y cáncer plantea nuevos retos en el abordaje del paciente con diabetes tipo 2, insulinorresistente, Hipertensión y Riesgo Vascular, 2015, 32, 1, 21

    CrossRef

  2. 2
    Kyong Hye Joung, Jae-Wook Jeong, Bon Jeong Ku, The Association between Type 2 Diabetes Mellitus and Women Cancer: The Epidemiological Evidences and Putative Mechanisms, BioMed Research International, 2015, 2015, 1

    CrossRef

  3. 3
    Shin-Jen Lin, Chang-Yi Lin, Dong-Rong Yang, Kouji Izumi, Emily Yan, Xiaodan Niu, Hong-Chiang Chang, Hiroshi Miyamoto, Nancy Wang, Gonghui Li, Chawnshang Chang, The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status, Neoplasia, 2015, 17, 4, 339

    CrossRef

  4. 4
    Shi Sen, Yanzheng He, Daisuke Koya, Keizo Kanasaki, Cancer biology in diabetes, Journal of Diabetes Investigation, 2014, 5, 3
  5. 5
    Leszek Szablewski, Diabetes mellitus: influences on cancer risk, Diabetes/Metabolism Research and Reviews, 2014, 30, 7
  6. 6
    H. C. Lin, Y. T. Hsu, B. H. Kachingwe, C. Y. Hsu, Y. S. Uang, L. H. Wang, Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study, Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 4
  7. 7
    Wu-jie Bu, Lei Song, Dan-yi Zhao, Bing Guo, Jing Liu, Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: a meta-analysis of observational studies, British Journal of Clinical Pharmacology, 2014, 78, 2
  8. 8
    E. Erdmann, E. Song, R. Spanheimer, A.-R. van Troostenburg de Bruyn, A. Perez, Observational follow-up of the PROactive study: a 6-year update, Diabetes, Obesity and Metabolism, 2014, 16, 1
  9. 9
    Bianka Bojková, Peter Orendáš, Peter Kubatka, Martin Péč, Monika Kassayová, Terézia Kisková, Karol Kajo, Positive and negative effects of glitazones in carcinogenesis: Experimental models vs. clinical practice, Pathology - Research and Practice, 2014, 210, 8, 465

    CrossRef

  10. 10
    Flavia Franconi, Ilaria Campesi, Sex and gender influences on pharmacological response: an overview, Expert Review of Clinical Pharmacology, 2014, 7, 4, 469

    CrossRef

  11. 11
    Matteo Monami, Ilaria Dicembrini, Edoardo Mannucci, Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials, Acta Diabetologica, 2014, 51, 1, 91

    CrossRef

  12. 12
    Raymond E. Soccio, Eric R. Chen, Mitchell A. Lazar, Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes, Cell Metabolism, 2014, 20, 4, 573

    CrossRef

  13. 13
    Shahzaib Ahmad, Tahseen A. Chowdhury, Barbara J. Boucher, Diabetes and cancer: Could vitamin D provide the link?, Journal of Diabetes and its Complications, 2013, 27, 2, 184

    CrossRef

  14. 14
    Jeremy J Walker, Jeffrey A Johnson, Sarah H Wild, Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure, The Lancet Diabetes & Endocrinology, 2013, 1, 2, 132

    CrossRef

  15. 15
    M. Ferwana, B. Firwana, R. Hasan, M. H. Al-Mallah, S. Kim, V. M. Montori, M. H. Murad, Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies, Diabetic Medicine, 2013, 30, 9
  16. 16
    S.W. Lai, K.F. Liao, Thiazolidinediones use and colorectal cancer risk, Diabetes & Metabolism, 2013, 39, 1, 88

    CrossRef

  17. 17
    Hala Ahmadieh, Sami T. Azar, Type 2 Diabetes Mellitus, Oral Diabetic Medications, Insulin Therapy, and Overall Breast Cancer Risk, ISRN Endocrinology, 2013, 2013, 1

    CrossRef

  18. 18
    Chia-Hsuin Chang, Jou-Wei Lin, Li-Chiu Wu, Mei-Shu Lai, Lee-Ming Chuang, K. Arnold Chan, Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus, Hepatology, 2012, 55, 5
  19. 19
    Adedayo A. Onitilo, Jessica M. Engel, Ingrid Glurich, Rachel V. Stankowski, Gail M. Williams, Suhail A. Doi, Diabetes and cancer II: role of diabetes medications and influence of shared risk factors, Cancer Causes & Control, 2012, 23, 7, 991

    CrossRef

  20. 20
    Michael Erbach, Hellmut Mehnert, Oliver Schnell, Diabetes and the risk for colorectal cancer, Journal of Diabetes and its Complications, 2012, 26, 1, 50

    CrossRef

  21. 21
    E. Fröhlich, R. Wahl, Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?, Diabetes, Obesity and Metabolism, 2012, 14, 3
  22. 22
    T. P. van Staa, D. Patel, A. M. Gallagher, M. L. de Bruin, Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data, Diabetologia, 2012, 55, 3, 654

    CrossRef

  23. 23
    I.N. Colmers, S.L. Bowker, L.A. Tjosvold, J.A. Johnson, Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies, Diabetes & Metabolism, 2012, 38, 6, 485

    CrossRef

  24. 24
    Joana Nicolau Ramis, Lluís Masmiquel Comas, Los nuevos antidiabéticos en el punto de mira… ¿razones de seguridad o caza de brujas?, Endocrinología y Nutrición, 2012, 59, 1, 1

    CrossRef

  25. 25
    Meera Penumetcha, Nalini Santanam, Nutraceuticals as Ligands of PPARγ, PPAR Research, 2012, 2012, 1

    CrossRef

  26. 26
    Joana Nicolau Ramis, Lluís Masmiquel Comas, The new antidiabetic agents in the firing line… safety reasons or witch hunt?, Endocrinología y Nutrición (English Edition), 2012, 59, 1, 1

    CrossRef

  27. 27
    I.N. Colmers, S.L. Bowker, J.A. Johnson, Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis, Diabetes & Metabolism, 2012, 38, 6, 475

    CrossRef

  28. 28
    Brandon L. Pierce, Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence, Urologic Oncology: Seminars and Original Investigations, 2012, 30, 5, 735

    CrossRef

  29. 29
    A. Ferrara, J. D. Lewis, C. P. Quesenberry, T. Peng, B. L. Strom, S. K. Van Den Eeden, S. F. Ehrlich, L. A. Habel, Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes, Diabetes Care, 2011, 34, 4, 923

    CrossRef

  30. 30
    J. A. Johnson, S. L. Bowker, Intensieve glucoseregulering en het risico op kanker bij type 2 diabetes: een meta-analyse van belangrijke trials, Nederlands Tijdschrift voor Diabetologie, 2011, 9, 2, 62

    CrossRef

  31. 31
    J. A. Johnson, S. L. Bowker, Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials, Diabetologia, 2011, 54, 1, 25

    CrossRef

  32. 32
    Bianka Bojková, Miroslava Garajová, Martin Péč, Peter Kubatka, Karol Kajo, Marián Mokáň, Monika Kassayová, Peter Orendáš, Terézia Kisková, Eva Ahlersová, Ivan Ahlers, Metabolic Effects of Pioglitazone in Chemically-Induced Mammary Carcinogenesis in Rats, Pathology & Oncology Research, 2011, 17, 4, 887

    CrossRef

  33. 33
    J. D. Lewis, A. Ferrara, T. Peng, M. Hedderson, W. B. Bilker, C. P. Quesenberry, D. J. Vaughn, L. Nessel, J. Selby, B. L. Strom, Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study, Diabetes Care, 2011, 34, 4, 916

    CrossRef

  34. 34
    Bin Bao, Zhiwei Wang, Yiwei Li, Dejuan Kong, Shadan Ali, Sanjeev Banerjee, Aamir Ahmad, Fazlul H. Sarkar, The complexities of obesity and diabetes with the development and progression of pancreatic cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011, 1815, 2, 135

    CrossRef

  35. 35
    Evanthia Gouveri, Nikolaos Papanas, Efstratios Maltezos, The female breast and diabetes, The Breast, 2011, 20, 3, 205

    CrossRef

  36. 36
    X.- X. He, S. M. Tu, M.- H. Lee, S.- C. J. Yeung, Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients, Annals of Oncology, 2011, 22, 12, 2640

    CrossRef

  37. 37
    E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, D. Yee, Diabetes and Cancer: A consensus report, Diabetes Care, 2010, 33, 7, 1674

    CrossRef

  38. 38
    Antonio Nicolucci, Epidemiological aspects of neoplasms in diabetes, Acta Diabetologica, 2010, 47, 2, 87

    CrossRef

  39. 39
    Christian Grommes, Devon S. Conway, Amer Alshekhlee, Jill S. Barnholtz-Sloan, Inverse association of PPARγ agonists use and high grade glioma development, Journal of Neuro-Oncology, 2010, 100, 2, 233

    CrossRef

  40. 40
    Jie Li, Stephen P. Motsko, Earl L. Goehring, Ruby Vendiola, Mary Maneno, Judith K. Jones, Longitudinal study on pediatric dyslipidemia in population-based claims database, Pharmacoepidemiology and Drug Safety, 2010, 19, 1
  41. 41
    Bianka Bojková, Miroslava Garajová, Karol Kajo, Martin Péč, Peter Kubatka, Monika Kassayová, Terézia Kisková, Peter Orendáš, Eva Ahlersová, Ivan Ahlers, Pioglitazone in chemically induced mammary carcinogenesis in rats, European Journal of Cancer Prevention, 2010, 19, 5, 379

    CrossRef

  42. 42
    Jie Li, Stephen P. Motsko, Earl L. Goehring, Arlene Tave, John C. Pezzullo, Judith K. Jones, Prevalence of pediatric dyslipidemia: comparison of a population-based claims database to national surveys, Pharmacoepidemiology and Drug Safety, 2010, 19, 10
  43. 43
    Raju C. Reddy, Anjaiah Srirangam, Kaunteya Reddy, Jun Chen, Srinivasareddy Gangireddy, Gregory P. Kalemkerian, Theodore J. Standiford, Venkateshwar G. Keshamouni, Chemotherapeutic Drugs Induce PPAR-γ Expression and Show Sequence-Specific Synergy with PPAR-γ Ligands in Inhibition of Non–Small Cell Lung Cancer, Neoplasia, 2008, 10, 6, 597

    CrossRef

  44. 44
    Brian M. Necela, E. Aubrey Thompson, Pathophysiological Roles of PPARγin Gastrointestinal Epithelial Cells, PPAR Research, 2008, 2008, 1

    CrossRef

  45. 45
    Ancha Baranova, PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes, PPAR Research, 2008, 2008, 1

    CrossRef

  46. 46
    Elke Burgermeister, Rony Seger, PPARγand MEK Interactions in Cancer, PPAR Research, 2008, 2008, 1

    CrossRef

  47. 47
    James D. Lewis, Gary R. Lichtenstein, Julius J. Deren, Bruce E. Sands, Stephen B. Hanauer, Jeffrey A. Katz, Bret Lashner, Daniel H. Present, Shaokun Chuai, Jonas H. Ellenberg, Lisa Nessel, Gary D. Wu, Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial, Gastroenterology, 2008, 134, 3, 688

    CrossRef

  48. 48
    James D. Lewis, Angela M. Capra, Ninah S. Achacoso, Assiamira Ferrara, Theodore R. Levin, Charles P. Quesenberry, Laurel A. Habel, Thiazolidinedione Therapy Is Not Associated With Increased Colonic Neoplasia Risk in Patients With Diabetes Mellitus, Gastroenterology, 2008, 135, 6, 1914

    CrossRef

  49. 49
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2007, 16, 9
  50. 50
    Raphael A. Nemenoff, Peroxisome Proliferator-Activated Receptor-?? in Lung Cancer: Defining Specific Versus ???Off-Target??? Effectors, Journal of Thoracic Oncology, 2007, 2, 11, 989

    CrossRef

  51. 51
    M. Lindberg, A. Astrup, The role of glitazones in management of type 2 diabetes. A DREAM or a nightmare?, Obesity Reviews, 2007, 8, 5